Breast cancer awareness doesn't end at diagnosis.
Patients still need answers about treatment, side effects, waiting, and what comes next.
STO’s latest blog explores the questions that matter and why some go unasked.
Read more: bit.ly/4ia4dOy
#BreastCancerAwareness
What AI does not know can matter as much as what it says.
Without full clinical context, a polished answer about cancer care may be incomplete or wrong.
Read STO’s perspective: bit.ly/4BgiFh4
#CancerCare #AIinHealthcare
Delays in breast cancer presentation, diagnosis, and treatment in young women buff.ly/U138pP0
Breast cancer treatment can affect menopause, intimacy, body image & relationships.
These aren't off-limits topics. They're health concerns worth discussing with your care team.
Aimee Faso & Amy DePue explain in Voices in Oncology. 🎧 bit.ly/4ihLgLd
#BreastCancer
A cancer diagnosis can leave patients asking: What happens now?
Fear, uncertainty, appointments & countless questions can collide in those first days.
Aimee Faso & Amy DePue discuss why early connection and a clear roadmap matter.
🎧 bit.ly/4yEPPVQ
#Oncology
AI can sound authoritative without knowing a patient’s history, medications, comorbidities, or treatment goals.
Fluency is not clinical expertise. Read STO’s latest: bit.ly/4jwZTLB
#AIinHealthcare #Oncology
Not every gynecologic cancer has a routine screening test.
Cervical cancer does. Several others don’t, making symptom awareness and risk assessment especially important.
Know what can be screened. Know what can’t.
Read more: bit.ly/4Av3zUd
#GynecologicCancer
"They presume it's not that serious." That's why patients stay quiet about symptoms and why adherence quietly slips.
Dr. Benyam Muluneh on the misconceptions clinicians have about medication adherence.
🎧 Part 2 of Voices in Oncology, out now. bit.ly/4y5pf80
Declining rural oncologist supply in the United States: a workforce analysis from 2014 to 2025 buff.ly/MNU5qp6
A missed pill is a symptom—not necessarily the problem. What’s underneath it?
Side effects. Cost. Access. Trust. Understanding.
Benyam Muluneh, PharmD, explores what oncology teams may be missing.
🎧 Listen now. bit.ly/46fgKei
#Oncology #CancerCare
“Gynecologic cancer” isn’t one disease.
Cervical, uterine, ovarian, vulvar & vaginal cancers have different risks, warning signs & approaches to detection.
Know the differences. Know what action to take.
bit.ly/4ho0u0E
#GynecologicCancerAwarenessMonth #WomensHealth
“AI suggested a different option.”
Patients are bringing AI-generated health information into appointments.
Our new Clinical Conversation Guide offers practical ways to respond with curiosity, context & collaboration.
Explore: bit.ly/45MpWqo
#Oncology #AIinHealthcare
Cancer care extends far beyond the clinic.
Jennifer McClendon of @NOCC joins Voices in Oncology to discuss how advocacy organizations help patients and caregivers navigate financial, insurance, emotional & practical challenges.
🎧 Listen: bit.ly/4hMZzI4
📬 New newsletter from STO
This issue features AI in the exam room, clinical trial representativeness, new Voices in Oncology episodes, and updates from the field: bit.ly/4x4e2nA
#AIinHealthcare #Oncology
HPV is common. Cervical cancer doesn’t have to be.
💉 Vaccinate
🔎Screen
❤️ Follow up
Download our new fact sheet: bit.ly/4xKjJa7
#HPV #CervicalCancer #CancerPrevention
AI can make patients feel more prepared, but not always more informed. Our latest article looks at how clinicians can keep the conversation clear, useful, and grounded in trust.
How is AI showing up in your conversations with patients? bit.ly/4wa1VUO
#AI #Oncology
⚡ If you think oncology pharmacists just dispense medication, this episode of Voices in Oncologywill change that. We dig into the role they play in education, access, toxicity management, and patient support. Listen now: bit.ly/4fFxtvw
“ChatGPT told me…” is becoming a real part of the patient voice. Our latest blog looks at how clinicians can respond with curiosity, context, and trust. bit.ly/4wa1VUO
#AIinHealthcare #PatientEngagement #ClinicalCommunication #PatientCenteredCare
Every trial contributes to oncology evidence, but only if results are shared. Our latest article looks at why publication matters, even when studies are negative or inconclusive. bit.ly/4wrKIan
Evaluating Geriatric Assessment and Interventions for Prostate Cancer buff.ly/XZ0WCiY




